<DOCUMENT>
<TYPE>EX-10.54
<SEQUENCE>5
<FILENAME>a2106640zex-10_54.htm
<DESCRIPTION>EXHIBIT 10.54
<TEXT>
<HTML>
<HEAD>

</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#03SAN1114_4">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>
<!-- TOC_END -->
<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="kg1114_exhibit_10.54"> </A>
<A NAME="toc_kg1114_1"> </A>
<BR></FONT><FONT SIZE=2><B>Exhibit 10.54    <BR>  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>AMENDMENT NO. 2  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Amendment No.&nbsp;2 ("Amendment No.&nbsp;2") to the Collaborative Research and License Agreement effective July&nbsp;9, 2001 ("Agreement") is made by
and between </FONT><FONT SIZE=2><B>ISIS PHARMACEUTICALS,&nbsp;INC.</B></FONT><FONT SIZE=2> ("Isis"), a Delaware corporation, with its principal office at 2292 Faraday Avenue, Carlsbad, California
92008 and </FONT><FONT SIZE=2><B>APPLERA CORPORATION,</B></FONT><FONT SIZE=2> a Delaware corporation, through the </FONT><FONT SIZE=2><B>CELERA GENOMICS GROUP</B></FONT><FONT SIZE=2>, ("Celera"),
having a principal place of business at 45 West Gude Drive, Rockville, Maryland 20850. Celera and Isis may be referred to herein individually as a "Party" and collectively as the "Parties." This
Amendment shall be effective as of the date of last signature below by an authorized representative of the Parties. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>WHEREAS</B></FONT><FONT SIZE=2>, PE Corporation (NY) through the Celera Genomics Group and Isis entered into the Agreement effective July&nbsp;9, 2001 to
collaborate to generate information on gene function for up to two-hundred fifty (250)&nbsp;gene targets; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>WHEREAS</B></FONT><FONT SIZE=2>, PE Corporation (NY) has been liquidated and all of its assets, subject to all of its liabilities, have been transferred to
Applera Corporation as of July&nbsp;1, 2002, and, in accordance with Section&nbsp;12.2 of the Agreement, the Agreement, and Amendment No.&nbsp;1 dated April&nbsp;22, 2002 shall be binding upon
Applera Corporation and shall be deemed to include the name of Applera Corporation to the extent necessary to carry out the intent of the Agreement and Amendment No.&nbsp;1 together with this
Amendment No.&nbsp;2. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>WHEREAS</B></FONT><FONT SIZE=2>, Celera and Isis desire to amend the Agreement to extend the Research Term. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>NOW, THEREFORE</B></FONT><FONT SIZE=2>, in consideration of the mutual covenants and promises contained herein, the Parties agree to amend the Agreement as
follows: </FONT></P>

<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>1.</FONT></DT><DD><FONT SIZE=2>Section&nbsp;1.40,
Research Term is hereby deleted and replaced with language that reads as follows: </FONT></DD></DL>

<UL>

<P><FONT SIZE=2>"Research
Term" means the period commencing on the Effective Date and terminating twenty three (23)&nbsp;months thereafter (or such earlier date as of which this Agreement is terminated hereunder). </FONT></P>

</UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>2.</FONT></DT><DD><FONT SIZE=2>This
Amendment will be attached to the Agreement and incorporated therein. All other terms of the Agreement will remain in full force and effect. </FONT></DD></DL>
</UL>
<BR>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TD COLSPAN=3 VALIGN="TOP"><FONT SIZE=2><B> APPLERA CORPORATION<BR>
Through the Celera Genomics Group</B></FONT></TD>
<TD WIDTH="5%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3 VALIGN="TOP"><FONT SIZE=2><B>ISIS PHARMACEUTICALS,&nbsp;INC.</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="5%"><BR><FONT SIZE=2>By:</FONT></TD>
<TD COLSPAN=2><FONT SIZE=2><BR>
/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>MARK D. ADAMS, PH.D.</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
<TD WIDTH="5%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD COLSPAN=2><FONT SIZE=2><BR>
/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>B. LYNNE PARSHALL</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="5%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>Name:</FONT></TD>
<TD WIDTH="35%"><FONT SIZE=2>Mark D. Adams, Ph.D.</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>Name:</FONT></TD>
<TD WIDTH="35%"><FONT SIZE=2>B. Lynne Parshall</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="5%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>Title:</FONT></TD>
<TD WIDTH="35%"><FONT SIZE=2>Vice President, Genome Programs</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>Title:</FONT></TD>
<TD WIDTH="35%"><FONT SIZE=2>Executive Vice President</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3><FONT SIZE=2><BR>
Date: January 15, 2003</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2><BR>
Date: January 22, 2003</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=1,EFW="2106640",CP="ISIS PHARMACEUTICALS, INC.",DN="4",CHK=441479,FOLIO='blank',FILE='DISK008:[03SAN4.03SAN1114]KG1114A.;4',USER='JHILL',CD='31-MAR-2003;13:35' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="03SAN1114_4">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2><A HREF="#toc_kg1114_1">Exhibit 10.54</A></FONT><BR>
</UL>
<!-- SEQ=,FILE='QUICKLINK',USER=SFLORES,SEQ=,EFW="2106640",CP="ISIS PHARMACEUTICALS, INC.",DN="4" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>

</TEXT>
</DOCUMENT>
